Financial Statements

Adaptimmune Therapeutics plc (ADAP)

$2.38

+0.13 (+5.78%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2021 2020 2019 2018 2017
Retained Earnings (Previous Year) -586-456-318-232-
Net Income -157-130-137-96-70
Stock Dividends -2--9-161
Dividend Paid -----
Retained Earnings -744-586-456-318-232

PPE Schedule

Year 2021 2020 2019 2018 2017
Gross PPE 47523641-
Annual Depreciation 13-219066
Capital Expenditure -9-3-3-5-25
Net PPE 5147523641

Intangible and Goodwill Schedule

Year 2021 2020 2019 2018 2017
Intangible and Goodwill (Previous Year) -----
New Purchases -171-151-27-381-
Intangible and Goodwill -----

Adaptimmune Therapeutics plc income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Adaptimmune Therapeutics plc FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.